NCT06880523
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06880523
Title STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Acronym SLIDE-HCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
Arthur J.E. Child Comprehensive Cancer Centre RECRUITING Calgary Alberta T2N 5G2 Canada Details
BCCA - Vancouver RECRUITING Vancouver British Columbia V5Z 4E6 Canada Details
Kingston Health Sciences Centre RECRUITING Kingston Ontario K7L 2V7 Canada Details
Waterloo Regional Health Network (WRHN) RECRUITING Kitchener Ontario N2G 1G3 Canada Details
London Health Sciences Centre Research Inc. RECRUITING London Ontario N6A 5W9 Canada Details
Trillium Health Partners - Credit Valley Hospital RECRUITING Mississauga Ontario L5M 2N1 Canada Details
Ottawa Hospital Research Institute RECRUITING Ottawa Ontario K1H 8L6 Canada Details
University Health Network RECRUITING Toronto Ontario M5G 2M9 Canada Details
CHUM-Centre Hospitalier de l'Universite de Montreal RECRUITING Montreal Quebec H2X 3E4 Canada Details
The Jewish General Hospital RECRUITING Montreal Quebec H3T 1E2 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field